BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 8659332)

  • 1. [Neoadjuvant hormone therapy with total radical prostatectomy: intermediate results].
    Hermans BP; Lorge F; Wese FX; Opsomer RJ; Van Cangh PJ
    Acta Urol Belg; 1996 Mar; 64(1):27-31. PubMed ID: 8659332
    [No Abstract]   [Full Text] [Related]  

  • 2. [Neoadjuvant hormonal therapy for prostate cancer].
    Miyakita H
    Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?
    Scolieri MJ; Altman A; Resnick MI
    J Urol; 2000 Nov; 164(5):1465-72. PubMed ID: 11025684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
    Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
    Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
    Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Radical prostatectomy with broadened scope of indications - analysis of early experience].
    Chakarov S; Bechev R; Lazarov Z; Fachikov Ts; Rangelov S
    Khirurgiia (Sofiia); 1999; 55(3):47-8. PubMed ID: 11194670
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Kinahan J; Sullivan LD
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):39-45; discussion 46-7. PubMed ID: 8725890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSA response to thalidomide in patients with advanced prostate cancer.
    Leibowitz R; Tucker SJ
    Oncology (Williston Park); 2002 Sep; 16(9):1146, 1148. PubMed ID: 12380944
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
    Miyake H; Hara I; Eto H
    BJU Int; 2005 Oct; 96(6):791-5. PubMed ID: 16153202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer.
    Wirth MP; Weissbach L; Marx FJ; Heckl W; Jellinghaus W; Riedmiller H; Noack B; Hinke A; Froehner M
    Eur Urol; 2004 Mar; 45(3):267-70; discussion 270. PubMed ID: 15036669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
    Boccon-Gibod L
    Prog Urol; 1997 Feb; 7(1):97-8. PubMed ID: 9116748
    [No Abstract]   [Full Text] [Related]  

  • 12. Neoadjuvant hormonal treatment before radical prostatectomy.
    Watson RB; Soloway MS
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):48-55; discussion 55-6. PubMed ID: 8725891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
    J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant hormone therapy and radical radiotherapy for localized prostate cancer: poorer biochemical outcome using flutamide alone.
    Wilson KS; Ludgate CM; Wilson AG; Alexander AS
    Can J Urol; 2000 Oct; 7(5):1099-103. PubMed ID: 11114872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Surgical and medical treatment for localized prostate cancer].
    Kawai K
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
    Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
    BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinoma of the prostate: neoadjuvant hormonotherapy followed by radiotherapy.
    Scalliet P
    Acta Urol Belg; 1996 May; 64(2):63-4. PubMed ID: 8701815
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
    Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
    Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary results of radical surgery and radiotherapy of locally advanced prostate cancer (basal PSA >50 ng/ml)].
    Kaprin AD; Khmelevskiĭ EV; Fadeev AV
    Vopr Onkol; 2007; 53(4):479-81. PubMed ID: 17969415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.